<DOC>
	<DOCNO>NCT00014287</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different way may kill tumor cell . PURPOSE : Phase I trial study effectiveness gemcitabine give directly bladder treat patient recurrent refractory bladder cancer .</brief_summary>
	<brief_title>Gemcitabine Treating Patients With Recurrent Refractory Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose intravesical gemcitabine patient recurrent refractory superficial bladder cancer . II . Determine dose-limiting toxicity toxic effect regimen patient . III . Assess responses patient treated regimen . OUTLINE : This dose-escalation , multicenter study . Patients receive intravesical gemcitabine leave bladder 2 hour remove day 1 . Treatment continue every 7 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos intravesical gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 3-36 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage Tis , Ta , T1 bladder carcinoma No stage B1 disease great No locally invasive metastatic disease CT MRI No upper urinary tract disease Measurable persistent recurrent superficial disease standard treatment intravesical BCG Stage Tis disease must fail second course BCG complete response achieve first course BCG Prior maximal transurethral resection Highgrade T1 Tis disease must ineligible cystectomy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception 1 week prior , , least 2 week study No active bacterial infection require treatment antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior immunotherapy Chemotherapy : Prior intravesical chemotherapy allow At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy bladder Surgery : See Disease Characteristics At least 2 week since prior transurethral resection bladder/bladder biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
</DOC>